相关实验视频
Updated: Jun 18, 2025
05:34
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
539
在CKD-G5D患者中冠状动脉疾病:最新情况
Pan Gao1, Xingjian Zou1, Xin Sun1
1Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Technology, 430022 Wuhan, Hubei, China.
Reviews in cardiovascular medicine
|July 30, 2024
概括
在透析中患有慢性病 (CKD-G5D) 的患者往往有无症状冠状动脉疾病 (CAD),这给管理带来了挑战. 这一审查强调了需要更好的风险评估和早期干预策略在这个人群中CAD.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 内部医学 内部医学
背景情况:
- 在透析中患有慢性病 (CKD-G5D) 的患者表现出冠状动脉疾病 (CAD) 的高患病率.
- 这一群体不同于患有CAD的非血性患者,并且历来被排除在临床试验之外.
- 在CKD-G5D患者中无症状的CAD复杂化了风险分层和管理.
研究的目的:
- 审查CKD-G5D患者中CAD的发病率,流行病学,病理生理学,查工具和治疗方法.
- 检查最近关于这种特定患者群体中CAD查工具和管理策略的研究.
- 强调需要加强心血管风险因素评估和早期干预,在CKD-G5D患者中治疗症状性CAD.
主要方法:
- 对CKD-G5D患者CAD现有研究的文献综述.
- 对有关查工具和管理策略的最新研究进行分析.
- 综合流行病学和病理生理学数据.
主要成果:
- 患有CKD-G5D的患者在CAD管理中存在独特的挑战,原因是与非uremic人群的差异.
- 目前的查工具和管理策略需要进一步评估这一队列的有效性.
- 显然需要改进的方法来早期识别和治疗CKD-G5D患者的CAD.
结论:
- 在CKD-G5D患者中有效管理CAD需要量身定制的方法.
- 进一步的研究对于优化查和干预策略至关重要.
- 早期检测和治疗对于改善CKD-G5D患者的治疗结果至关重要.
相关概念视频
01:11Renal Failure: Dose Adjustments
77
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
77
01:17Ischemic Heart Disease: Overview
1.2K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.2K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
152
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
152
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
141
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
141
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
490
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
490